Cannalean Biotechs
CBD-based Solutions for Treating Dyslipidemia
StartupCannalean Biotechs is a Bnei Brak-based startup in the Health Tech & Life Sciences sector, established in 2018. CBD-based Solutions for Treating Dyslipidemia. Cannalean Biotechs was founded by David Bassa. The company has 1-10 employees. Core technologies: Biologicals, Herbals.
The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePre-Funding
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQBnei Brak
- DistrictCenter District
- Last RoundUndisclosed
David BassaCEO
3 articles covered by sources including www.prnewswire.com,
www.healtheuropa.eu.
What does Cannalean Biotechs do?
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia. CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction. CannaLean Biotechs was established in partnership with Mor Research Applications.
Who founded Cannalean Biotechs?
Cannalean Biotechs was founded in 2018 by David Bassa (CEO).
What sector is Cannalean Biotechs in?
Cannalean Biotechs operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Medical Cannabis, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.
Where is Cannalean Biotechs located?
Cannalean Biotechs is based in Baruch Hirsch Street 14, Bnei Brak, Israel, Center District.